UroGen Pharma Ltd.
HealthcareNASDAQ:URGN · NASDAQ Global Market
+$0.22 today
Vol 0.58M · Avg 0.80M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $111.3M |
| Short-term Investments | $30.3M |
| Receivables | $55.4M |
| Inventory | $20.9M |
| Other Current | $19.5M |
| Total Current Assets | $237.5M |
| PP&E (Net) | $8.6M |
| Long-term Investments | $177.0K |
| Other Non-current | $7.5M |
| Total Non-current Assets | $16.2M |
| Total Assets | $253.7M |
Analysis
Selected assets total $253.7M for Latest. The largest visible component is Cash & Equivalents at $111.3M, about 43.9% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $110.7M -35.6% | $172.0M +81.0% | $95.0M +71.5% | $55.4M +24.9% | $44.4M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $9.7M -85.0% | $64.7M +54.2% | $42.0M -5.8% | $44.6M -0.5% | $44.8M | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $33.1M +62.9% | $20.3M +31.5% | $15.4M +21.6% | $12.7M +8.4% | $11.7M | $533.8M | $399.4M | -$1.7B |
| Inventory | $16.5M +78.4% | $9.2M +62.6% | $5.7M +31.2% | $4.3M -10.5% | $4.8M | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $16.0M +61.5% | $9.9M -10.6% | $11.1M -6.8% | $11.9M +871.8% | $1.2M | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $186.0M -32.6% | $276.1M +63.2% | $169.2M +31.2% | $128.9M +12.7% | $114.4M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $9.1M +140.0% | $3.8M +60.6% | $2.4M -37.0% | $3.7M +19.1% | $3.1M | $1.2B | $1.5B | $687.8M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $0 -100.0% | $5.0M +11.6% | $4.5M | $0 -100.0% | $675.0K | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $5.3M +597.8% | $765.0K -66.2% | $2.3M -23.6% | $3.0M +93.2% | $1.5M | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $14.4M +50.7% | $9.6M +4.9% | $9.1M +36.0% | $6.7M +25.3% | $5.4M | -$15.3B | $14.8B | $11.3B |
| Total Assets | $200.5M -29.8% | $285.7M +60.2% | $178.3M +31.5% | $135.6M +13.3% | $119.7M | $13.3B | $11.9B | $10.6B |
| Account Payables | $12.1M +11.0% | $10.9M +67.8% | $6.5M +17.9% | $5.5M -4.5% | $5.8M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $0 | $0 | $0 | $0 | $0 | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 | $0 | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $34.3M +85.1% | $18.5M +26.2% | $14.7M +27.2% | $11.5M +12.2% | $10.3M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $46.4M +1.0% | $45.9M +47.2% | $31.2M +30.5% | $23.9M +6.9% | $22.4M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $122.2M +0.4% | $121.7M +23.5% | $98.6M +1.0% | $97.5M | $0 | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 -100.0% | $3.0M +6.2% | $2.8M | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $131.2M +4.8% | $125.2M +10.9% | $112.9M +14.1% | $98.9M +15.4% | $85.7M | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $259.5M +4.4% | $248.6M +17.1% | $212.3M +5.6% | $201.1M +126.0% | $89.0M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $305.9M +3.9% | $294.5M +20.9% | $243.5M +8.2% | $225.0M +102.1% | $111.3M | $14.7B | $3.7B | $9.6B |
| Common Stock | $133.0K +15.7% | $115.0K +29.2% | $89.0K +41.3% | $63.0K +3.3% | $61.0K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$959.7M -19.0% | -$806.2M -18.7% | -$679.3M -17.7% | -$577.1M -23.5% | -$467.3M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $19.0K -66.1% | $56.0K +366.7% | $12.0K +111.2% | -$107.0K -328.0% | -$25.0K | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | -$105.5M -1098.2% | -$8.8M +86.5% | -$65.2M +27.0% | -$89.4M -1162.2% | $8.4M | $9.1B | $7.7B | $3.3B |
| Total Debt | $128.3M +4.0% | $123.4M +24.1% | $99.4M +0.3% | $99.1M +24805.3% | $398.0K | $724.2M | $410.6M | $399.4M |
| Net Debt | $17.6M +136.2% | -$48.6M -1206.3% | $4.4M -90.0% | $43.7M +199.4% | -$44.0M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Tango Therapeutics, Inc.
NASDAQ:TNGX
$3.59B
AnaptysBio, Inc.
NASDAQ:ANAB
$2.42B
Kodiak Sciences Inc.
NASDAQ:KOD
$1.80B
Mind Medicine (MindMed) Inc.
MNMD
$1.56B
Nurix Therapeutics, Inc.
NASDAQ:NRIX
$1.47B
Xencor, Inc.
NASDAQ:XNCR
$914.17M
Phathom Pharmaceuticals, Inc.
NASDAQ:PHAT
$827.07M
Oculis Holding AG
NASDAQ:OCS
$634.01M
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
$620.83M
ProKidney Corp.
NASDAQ:PROK
$242.99M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does URGN have?
UroGen Pharma Ltd. (URGN) reported $110.75M in cash and equivalents in fiscal 2025.
How much debt does URGN carry?
UroGen Pharma Ltd. (URGN) reported $128.33M of total debt, with net debt of $17.59M.
Explore More
Continue the stock analysis
Jump to another research area for this company.